BD PharmingenTM APC Rat anti-Human TLR9

Description

Flow cytometric analysis of APC anti-human TLR9 on resting PBMC. Human PBMC were fixed and permeabilized using BD Cytofix/Cytoperm reagents Cat. No. 554714 followed by staining with APC anti-human TLR9, PerCP-Cy5.5 anti-human HLA-DR Cat. No. 339194 and PE anti-human CD123 Cat. No. 554529, left panel or FITC anti-human CD11c Clone B-ly6, right panel . The dot plots were derived from a HLA-DR+ gate. Flow cytometry was performed on a BD FACSCalibur System. Flow cytometric analysis of APC anti-human TLR9 on resting PBMC. Human PBMC were fixed and permeabilized using BD Cytofix/Cytoperm reagents Cat. No. 554714 followed by staining with APC anti-human TLR9, PerCP-Cy5.5 anti-human HLA-DR Cat. No. 339194 and PE anti-human CD123 Cat. No. 554529, left panel or FITC anti-human CD11c Clone B-ly6, right panel . The dot plots were derived from a HLA-DR+ gate. Flow cytometry was performed on a BD FACSCalibur System. Flow cytometric analysis of APC anti-human TLR9 on resting PBMC. Human PBMC were fixed and permeabilized using BD Cytofix/Cytoperm reagents Cat. No. 554714 followed by staining with APC anti-human TLR9, PerCP-Cy5.5 anti-human HLA-DR Cat. No. 339194 and PE anti-human CD123 Cat. No. 554529, left panel or FITC anti-human CD11c Clone B-ly6, right panel . The dot plots were derived from a HLA-DR+ gate. Flow cytometry was performed on a BD FACSCalibur System. Show More Flow cytometric analysis of APC anti-human TLR9 on resting PBMC. Human PBMC were fixed and permeabilized using BD Cytofix/Cytoperm reagents Cat. No. 554714 followed by staining with APC anti-human TLR9, PerCP-Cy5.5 anti-human HLA-DR Cat. No. 339194 and PE anti-human CD123 Cat. No. 554529, left panel or FITC anti-human CD11c Clone B-ly6, right panel . The dot plots were derived from a HLA-DR+ gate. Flow cytometry was performed on a BD FACSCalibur System. Show More Flow cytometric analysis of APC anti-human TLR9 on resting PBMC. Human PBMC were fixed and permeabilized using BD Cytofix/Cytoperm reagents Cat. No. 554714 followed by staining with APC anti-human TLR9, PerCP-Cy5.5 anti-human HLA-DR Cat. No. 339194 and PE anti-human CD123 Cat. No. 554529, left panel or FITC anti-human CD11c Clone B-ly6, right panel . The dot plots were derived from a HLA-DR+ gate. Flow cytometry was performed on a BD FACSCalibur System. Flow cytometric analysis of APC anti-human TLR9 on resting PBMC. Human PBMC were fixed and permeabilized using BD Cytofix/Cytoperm reagents Cat. No. 554714 followed by staining with APC anti-human TLR9, PerCP-Cy5.5 anti-human HLA-DR Cat. No. 339194 and PE anti-human CD123 Cat. No. 554529, left panel or FITC anti-human CD11c Clone B-ly6, right panel . The dot plots were derived from a HLA-DR+ gate. Flow cytometry was performed on a BD FACSCalibur System.